相关实验视频

Updated: Jun 28, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

解锁过度表达的膜蛋白来引导乳腺癌精密医学

Júlia Badaró Mendonça^1,2, Priscila Valverde Fernandes³, Danielle C Fernandes³

¹Translational Oncology Platform, Center for Technological Development in Health, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-900, RJ, Brazil.

|April 13, 2024

概括

新的研究确定了四种膜蛋白 (LRRC15,EFNA3,TSPAN13,CA12) 作为乳腺癌 (BC) 诊断和治疗的有希望的生物标志物. 这些蛋白质在瘤中表达的增加,为改善治疗和减少副作用提供了潜力.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
生物信息学是一种生物信息学.

背景情况:

乳腺癌 (BC) 是一个重大的全球健康挑战,目前的治疗受到毒性,耐药性和副作用的阻碍.
在BC管理中,急需新的治疗点和增强瘤追踪方法.

研究的目的:

开发一种策略来识别瘤特异性膜蛋白,用于向的BC治疗和诊断.
评估已识别的膜蛋白作为BC检测和治疗的生物标记物的潜力.

主要方法:

来自癌症基因组图谱 (TCGA),UALCAN,TNM Plot和LinkedOmics的基因表达数据的综合生物信息学分析.
对乳腺瘤,非瘤和健康组织进行分析,以确定差异表达的膜蛋白.
在分子亚型中使用接收器操作特征 (ROC) 曲线和组织微阵列 (TMA) 分析进行验证.

主要成果:

与健康组织相比,四种编码膜蛋白的转录 (LRRC15,EFNA3,TSPAN13,CA12) 在BC组织中显著增加表达.
这些蛋白质在识别瘤样本方面表现出高精度和特异性,ROC曲线分析证实了这一点.
TMA分析证实了所有分子亚型的瘤中蛋白质表达的升高;互动组数据突出显示了它们在癌症途径中的作用.

结论:

已确定LRRC15,EFNA3,TSPAN13和CA12是改善乳腺癌诊断和查的潜在生物标志物.
这些蛋白质代表了有希望的治疗点,用于开发更有效的BC治疗,潜在的副作用更少.

关键词:

乳腺癌乳腺癌乳腺癌诊断诊断诊断诊断诊断诊断分子目标是分子目标.精确瘤学精确瘤学治疗疗法治疗疗法治疗疗法

更多相关视频

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...